cyclosporine has been researched along with Devic Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, X; Li, Y; Lin, Y; Liu, X; Shi, S; Shi, Z; Wen, D; Wu, Y; Yang, M; Yao, J; You, C; Yu, Z; Zhao, Z; Zhou, H | 1 |
| Kageyama, T; Komori, M; Kondo, T; Kusunoki, S; Matsumoto, S; Miyamoto, K; Ozaki, A; Suenaga, T; Takahashi, R | 1 |
2 other study(ies) available for cyclosporine and Devic Disease
| Article | Year |
|---|---|
The immune regulatory effects of tetrahedral framework nucleic acid on human T cells via the mitogen-activated protein kinase pathway.
Topics: Adult; Cells, Cultured; Cyclosporine; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Interferon-gamma; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Middle Aged; Mitogen-Activated Protein Kinases; Nanostructures; Neuromyelitis Optica; Nucleic Acids; Phosphorylation; T-Lymphocytes; Tumor Necrosis Factor-alpha; Young Adult | 2021 |
Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies; Aquaporin 4; Azathioprine; Cyclosporine; Disability Evaluation; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Neuromyelitis Optica; Treatment Outcome | 2013 |